Illumina Inc. (NASDAQ: ILMN) shares dipped early Monday after the company announced that it would be making a critical acquisition. Grail is the target in this case, and Illumina’s acquisition makes moot Grail’s previous plan to come public in an initial public offering.
What stands out here is that Grail was spun out from Illumina as a standalone company in 2016. It uses Illumina’s NGS technology to develop state-of-the-art data science and machine learning and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests.
Grail’s management believes that its multi-cancer early detection test, Galleri, can lead to a dramatic increase in early cancer diagnosis. The test is designed as a screening test for asymptomatic individuals over 50 years of age and is currently in late-stage development. Grail previously said that it plans to launch Galleri commercially in 2021 as a laboratory developed test.
Under the terms of the deal, Illumina will acquire Grail for $8 billion in a cash and stock agreement. Additionally, Grail stockholders will receive future payments representing a tiered single-digit percentage of certain Grail-related revenues.
The $8 billion price tag consists of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. Currently, Illumina holds 14.5% of Grail’s shares.
The agreement has been approved by the boards of directors of Illumina and Grail. The transaction is expected to close in the second half of 2021.
After all is said and done, Grail will operate as a standalone division within Illumina, with a dedicated leadership team to ensure continuation of Grail’s success.
Illumina stock traded down about 8% Monday morning, at $271.76 in a 52-week range of $196.78 to $404.20. The consensus price target is $351.33.
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
